 | Up a level |
2018
Cohen, J. B., Engert, A., Ansell, S. M., Younes, A., Trneny, M., Savage, K. J., Ramchandren, R., Collins, G. P., Fanale, M. A., Armand, P., Zinzani, P. L., de Boer, J. P., Shipp, M. A., Santoro, A., Timmerman, J. M., Sacchi, M., Sy, O. and Kuruvilla, J. (2018). Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 205 Study. Br. J. Haematol., 181. S. 87 - 89. HOBOKEN: WILEY. ISSN 1365-2141
2016
Moskowitz, C., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N., Ribrag, V., Radford, J., von Tresckow, B., Tomita, A., Shipp, M. A., Wang, Y., Ricart, A. D., Balakumaran, A. and Chen, R. (2016). MULTICOHORT PHASE 2 STUDY OF PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL): KEYNOTE-087. Haematologica, 101. S. 319 - 320. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078